12 results on '"Goldstein, Daniel"'
Search Results
2. Left ventricular assist devices and bleeding: adding insult to injury.
- Author
-
Goldstein, Daniel J. and Beauford, Robert B.
- Subjects
HEMORRHAGE ,SURGICAL complications ,LEFT heart ventricle ,BLOOD transfusion (Islamic law) - Abstract
Bleeding is the most common postoperative complication after implantation of left ventricular assist devices, necessitating reoperation in up to 60% of recipients. The implications of massive blood transfusions are great and include infection, pulmonary insufficiency, increased costs, right heart failure, allosensitization, and viral transmission, some of which can prove fatal or preclude transplantation. Preoperative evaluation and preparation are essential, intraoperative hemostasis is imperative, and “shotgun” product replacement should be avoided. Adherence to protocols emphasizing “hemostatic readiness” could reduce the incidence of bleeding complications that pervade left ventricular assist device therapy and potentially improve current successes in bridging to transplantation. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
3. Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices.
- Author
-
Ascheim, Deborah D., Gelijns, Annetine C., Goldstein, Daniel, Moye, Lemuel A., Smedira, Nicholas, Lee, Sangjin, Klodell, Charles T., Szady, Anita, Parides, Michael K., Jeffries, Neal O., Skerrett, Donna, Taylor, Doris A., Rame, J. Eduardo, Milano, Carmelo, Rogers, Joseph G., Lynch, Janine, Dewey, Todd, Eichhorn, Eric, Sun, Benjamin, and Feldman, David
- Subjects
- *
MESENCHYMAL stem cells , *LEFT heart ventricle , *ARTIFICIAL implants , *CLINICAL trials , *TREATMENT of myocarditis - Abstract
Background--Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy. Methods and Results--In this multicenter, double-blind, sham-procedure controlled trial, 30 patients were randomized (2:1) to intramyocardial injection of 25 million MPCs or medium during LVAD implantation. The primary safety end point was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days after randomization). Key efficacy end points were functional status and ventricular function while temporarily weaned from LVAD support (90 days after randomization). Patients were followed up until transplant or 12 months after randomization, whichever came first. Mean age was 57.4 (±13.6) years, mean left ventricular ejection fraction was 18.1%, and 66.7% were destination therapy LVADs. No safety events were observed. Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients at 90 days (P=0.24); the posterior probability that MPCs increased the likelihood of successful weaning was 93%. At 90 days, 3 deaths (30%) occurred in control patients, and none occurred in MPC patients. Mean left ventricular ejection fraction after successful wean was 24.0% (MPC=10) and 22.5% (control=2; P=0.56). At 12 months, 30% of MPC patients and 40% of control patients were successfully temporarily weaned from LVAD support (P=0.69), and 6 deaths (30%) occurred in MPC patients. Donor-specific HLA sensitization developed in 2 MPC and 3 control patients and resolved by 12 months. Conclusions--In this preliminary trial, administration of MPCs appeared to be safe, and there was a potential signal of efficacy. Future studies will evaluate the potential for higher or additional doses to enhance the ability to wean LVAD recipients off support. Clinical Trial Registration--URL: http://www.clinicaltrials.gov. Unique identifier: NCT01442129. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
4. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results.
- Author
-
Birks, Emma J., Drakos, Stavros G., Patel, Snehal R., Lowes, Brian D., Selzman, Craig H., Starling, Randall C., Trivedi, Jaimin, Slaughter, Mark S., Alturi, Pavin, Goldstein, Daniel, Maybaum, Simon, Um, John Y., Margulies, Kenneth B., Stehlik, Josef, Cunningham, Christopher, Farrar, David J., and Rame, Jesus E.
- Subjects
- *
VENTRICULAR ejection fraction , *HEART assist devices , *HEART failure , *LONGITUDINAL method , *PULMONARY artery , *ECHOCARDIOGRAPHY , *LEFT heart ventricle , *MEDICAL device removal , *CLINICAL trials , *CONVALESCENCE , *HEART physiology , *DISEASE remission - Abstract
Background: Left ventricular assist device (LVAD) unloading and hemodynamic support in patients with advanced chronic heart failure can result in significant improvement in cardiac function allowing LVAD removal; however, the rate of this is generally considered to be low. This prospective multicenter nonrandomized study (RESTAGE-HF [Remission from Stage D Heart Failure]) investigated whether a protocol of optimized LVAD mechanical unloading, combined with standardized specific pharmacological therapy to induce reverse remodeling and regular testing of underlying myocardial function, could produce a higher incidence of LVAD explantation.Methods: Forty patients with chronic advanced heart failure from nonischemic cardiomyopathy receiving the Heartmate II LVAD were enrolled from 6 centers. LVAD speed was optimized with an aggressive pharmacological regimen, and regular echocardiograms were performed at reduced LVAD speed (6000 rpm, no net flow) to test underlying myocardial function. The primary end point was the proportion of patients with sufficient improvement of myocardial function to reach criteria for explantation within 18 months with sustained remission from heart failure (freedom from transplant/ventricular assist device/death) at 12 months.Results: Before LVAD, age was 35.1±10.8 years, 67.5% were men, heart failure mean duration was 20.8±20.6 months, 95% required inotropic and 20% temporary mechanical support, left ventricular ejection fraction was 14.5±5.3%, end-diastolic diameter was 7.33±0.89 cm, end-systolic diameter was 6.74±0.88 cm, pulmonary artery saturations were 46.7±9.2%, and pulmonary capillary wedge pressure was 26.2±7.6 mm Hg. Four enrolled patients did not undergo the protocol because of medical complications unrelated to the study procedures. Overall, 40% of all enrolled (16/40) patients achieved the primary end point, P<0.0001, with 50% (18/36) of patients receiving the protocol being explanted within 18 months (pre-explant left ventricular ejection fraction, 57±8%; end-diastolic diameter, 4.81±0.58 cm; end-systolic diameter, 3.53±0.51 cm; pulmonary capillary wedge pressure, 8.1±3.1 mm Hg; pulmonary artery saturations 63.6±6.8% at 6000 rpm). Overall, 19 patients were explanted (19/36, 52.3% of those receiving the protocol). The 15 ongoing explanted patients are now 2.26±0.97 years after explant. After explantation survival free from LVAD or transplantation was 90% at 1-year and 77% at 2 and 3 years.Conclusions: In this multicenter prospective study, this strategy of LVAD support combined with a standardized pharmacological and cardiac function monitoring protocol resulted in a high rate of LVAD explantation and was feasible and reproducible with explants occurring in all 6 participating sites. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01774656. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
5. Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study.
- Author
-
Colombo, Paolo C., Mehra, Mandeep R., Downey, Francis X., Ono, Masahiro, Hooker, Robert, Anyanwu, Anelechi C., Mahr, Claudius, Topuria, Ia, Somo, Sami I., Crandall, Daniel L., Horstmanshof, Douglas A., Cleveland, Joseph C Jr, Hooker, Robert Jr, Givertz, Michael M., Goldstein, Daniel J., Jorde, Ulrich P., Estep, Jerry D., Salerno, Christopher, Cowger, Jennifer A., and Cleveland, Joseph C.
- Subjects
- *
HEART assist devices , *RANDOMIZED controlled trials , *CLINICAL trial registries , *STROKE , *BLOOD pressure , *HEART failure treatment , *STROKE prevention , *STROKE diagnosis , *STROKE-related mortality , *CEREBRAL hemorrhage , *CEREBRAL ischemia , *COMPARATIVE studies , *LEFT heart ventricle , *HEART physiology , *HEART failure , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *PROSTHETICS , *RESEARCH , *RISK assessment , *TIME , *EVALUATION research , *TREATMENT effectiveness , *SEVERITY of illness index - Abstract
Background: The MOMENTUM 3 study (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) has demonstrated that the HeartMate 3 (HM3) pump is associated with reduced strokes compared with the HeartMate II (HMII) device. We now perform a comprehensive analysis of stroke events to evaluate their longitudinal occurrence, clinical correlates, patterns, and impact on outcome across the 2-year duration of support.Methods: MOMENTUM 3 is a randomized controlled trial of the HM3 centrifugal-flow pump versus the HMII axial-flow pump in patients with advanced heart failure, regardless of the intended goal of support (bridge to transplantation or destination therapy). Baseline and postimplantation clinical correlates of stroke events were assessed with multivariable analyses. Longitudinal patterns, including device association, type of stroke (hemorrhagic versus ischemic), changing severity of impairment assessed with the modified Rankin Scale (disabling [modified Rankin Scale score >3] versus nondisabling [modified Rankin Scale score ≤3]) over time, and association with outcome, were determined.Results: In 361 patients with the intended implant (189 HM3 and 172 HMII), 65 strokes (40 ischemic strokes and 25 hemorrhagic strokes) occurred in 52 patients at a median of 131 (range, 1-733) days. No difference in stroke rate was noted between 0 and 180 days of follow-up between devices. However, stroke incidence in the long-term period (181-730 days after left ventricular assist device) was 3.3 times lower for the HM3 group (HM3: 0.04 versus HMII: 0.13 events per patient-year; odds ratio, 0.23; 95% CI, 0.08-0.63; P=0.01). Treatment with the HM3 pump was the only independent predictor of lower stroke events. We found no direct association of blood pressure or antithrombotic regimens with observed stroke rates. A stroke event significantly lowered 2-year postimplantation survival regardless of subtype or initial severity of neurological impairment compared with patients without a stroke (43±12% for hemorrhagic stroke, 57±9% for ischemic stroke, 51±11% for disabling, and 51±11% for nondisabling compared with 85±2% 2-year survival for patients without stroke).Conclusions: The HM3 pump is associated with a marked reduction in stroke rates compared with the HMII device, with benefits observed in the long-term period (>6 months). The occurrence of stroke of any type (hemorrhagic and ischemic) or of any functional severity (disabling and nondisabling) is predictive of a poor 2-year clinical outcome.Clinical Trial Registration: URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT02224755. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.
- Author
-
Forest, Stephen J., Xie, Rongbing, Kirklin, James K., Cowger, Jennifer, Xia, Yu, Dipchand, Anne I., Sivathasan, Cumara, Merry, Chris, Lund, Lars H., Kormos, Robert, Hannan, Margaret M., Nakatani, Takeshi, Jorde, Ulrich, and Goldstein, Daniel J.
- Subjects
- *
BODY mass index , *LEFT heart ventricle , *ARTIFICIAL implants , *CARDIAC surgery , *HEART transplantation - Abstract
BACKGROUND Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Outcomes After Transplantation of Donor Hearts With Improving Left Ventricular Systolic Dysfunction.
- Author
-
Madan, Shivank, Saeed, Omar, Vlismas, Peter, Katsa, Ioanna, Patel, Snehal R., Shin, Julia J., Jakobleff, William A., Goldstein, Daniel J., Sims, Daniel B., and Jorde, Ulrich P.
- Subjects
- *
HEART transplantation , *ORGAN donors , *CARDIAC contraction , *LEFT heart ventricle diseases , *BRAIN death , *HEART physiology , *LEFT heart ventricle surgery , *HEART ventricle diseases , *COMPARATIVE studies , *ECHOCARDIOGRAPHY , *GRAFT versus host reaction , *LEFT heart ventricle , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *TRANSPLANTATION of organs, tissues, etc. , *EVALUATION research , *RETROSPECTIVE studies , *STROKE volume (Cardiac output) , *DIAGNOSIS - Abstract
Background: Left ventricular systolic dysfunction (LVSD) accounts for almost 25% of nonacceptance of potential donor hearts. Previous smaller, single-center studies showed that LVSD following brain death may be transient, and such hearts can be successfully resuscitated with resolution of LVSD, then transplanted.Objectives: This study evaluated outcomes of donor hearts with LVSD on initial transthoracic echocardiogram (TTE) that resolved during donor management.Methods: We reviewed echocardiograms of all cardiac donors in the United Network of Organ Sharing database that were transplanted from January 1, 2007, to September 30, 2015, and identified 472 donor hearts with LVSD (left ventricular ejection fraction [LVEF] ≤40%) on initial TTE that resolved (LVEF ≥50%) during donor management on a subsequent TTE. These patients comprised the improved donor LVEF group. These were compared with donor hearts with normal LVEF (LVEF ≥55%) on the initial TTE for recipient mortality, cardiac allograft vasculopathy (CAV), and primary graft failure (PGF).Results: There was no significant difference in recipient mortality at 30 days, 1 year, 3 years, and 5 years of follow-up, nor any difference in rates of PGF at 90 days and CAV at 5 years between recipients of donor hearts with improved LVEF and recipients of donor hearts with initially normal LVEF. Post-transplant length of stay was also similar between the 2 groups. Using propensity scores, 461 transplants in the improved-donor LVEF group were matched to 461 transplants in the normal-donor LVEF group. There was no significant difference in PGF at 90 days or recipient mortality after up to 5 years of follow-up.Conclusions: In the largest analysis of donor hearts with transient LVSD, we found that such hearts can be successfully resuscitated and transplanted without increasing recipient mortality, CAV, or PGF. These results underscore the importance of appropriate donor management and should help to increase utilization of donor hearts with transient LVSD. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
8. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
- Author
-
Uriel, Nir, Colombo, Paolo C., Cleveland, Joseph C., Long, James W., Salerno, Christopher, Goldstein, Daniel J., Patel, Chetan B., Ewald, Gregory A., Tatooles, Antone J., Silvestry, Scott C., John, Ranjit, Caldeira, Christiano, Jeevanandam, Valluvan, Boyle, Andrew J., Sundareswaran, Kartik S., Sood, Poornima, and Mehra, Mandeep R.
- Subjects
- *
COMPLICATIONS of artificial blood circulation , *HEART failure treatment , *LEFT heart ventricle surgery , *LEFT heart ventricle , *CARDIAC patients , *DISEASE risk factors , *COMPARATIVE studies , *HEART physiology , *HEART failure , *HEMOLYSIS & hemolysins , *LONGITUDINAL method , *MAGNETS , *MATERIALS testing , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RESEARCH , *STROKE , *THROMBOSIS , *TIME , *PRODUCT design , *EVALUATION research , *PHYSIOLOGIC strain , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *MEDICAL equipment reliability , *MEDICAL device removal , *HEART assist devices , *KAPLAN-Meier estimator , *ODDS ratio , *DIAGNOSIS - Abstract
Background: The HeartMate 3 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated, continuous-flow blood pump engineered to enhance hemocompatibility and reduce shear stress on blood components. The MOMENTUM 3 trial (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares the HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical management, irrespective of therapeutic intention (bridge to transplant versus destination therapy). This investigation reported its primary outcome in the short-term cohort (n=294; 6-month follow-up), demonstrating superiority of the HM3 for the trial primary end point (survival free of a disabling stroke or reoperation to replace the pump for malfunction), driven by a reduced need for reoperations. The aim of this analysis was to evaluate the aggregate of hemocompatibility-related clinical adverse events (HRAEs) between the 2 LVAS.Methods: We conducted a secondary end point evaluation of HRAE (survival free of any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological event) in the short-term cohort (as-treated cohort n=289) at 6 months. The net burden of HRAE was also assessed by using a previously described hemocompatibility score, which uses 4 escalating tiers of hierarchal severity to derive a total score for events encountered during the entire follow-up experience for each patient.Results: In 289 patients in the as-treated group (151 the HM3 and 138 the HMII), survival free of any HRAE was achieved in 69% of the HM3 group and in 55% of the HMII group (hazard ratio, 0.62; confidence interval, 0.42-0.91; P=0.012). Using the hemocompatibility score, the HM3 group demonstrated less pump thrombosis requiring reoperation (0 versus 36 points, P<0.001) or medically managed pump thrombosis (0 versus 5 points, P=0.02), and fewer nondisabling strokes (6 versus 24 points, P=0.026) than the control HMII LVAS. The net hemocompatibility score in the HM3 in comparison with the HMII patients was 101 (0.67±1.50 points/patient) versus 137 (0.99±1.79 points/patient) (odds ratio, 0.64; confidence interval, 0.39-1.03; P=0.065).Conclusions: In this secondary analysis of the MOMENTUM 3 trial, the HM3 LVAS demonstrated greater freedom from HRAEs in comparison with the HMII LVAS at 6 months.Clinical Trial Registration: URL: http://clinicaltrials.gov. Unique identifier: NCT02224755. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
9. The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy.
- Author
-
Pagani, Francis D., Aaronson, Keith D., Kormos, Robert, Mann, Douglas L., Spino, Cathie, Jeffries, Neal, Taddei-Peters, Wendy C., Mancini, Donna M., McNamara, Dennis M., Grady, Kathleen L., IIIGorcsan, John, Petrucci, Ralph, Anderson, Allen S., Glick, Henry A., Acker, Michael A., Eduardo Rame, J., Goldstein, Daniel J., Pamboukian, Salpy V., Miller, Marissa A., and Timothy Baldwin, J.
- Subjects
- *
LEFT heart ventricle , *QUALITY of life , *HEART failure treatment , *CLINICAL trials - Abstract
The National Institutes of Health National Heart, Lung, and Blood Institute convened a working group in March 2008 to discuss how therapies for heart failure (HF) might be best advanced using clinical trials involving left ventricular assist devices (LVAD). This group opined that the field was ready for a trial to assess the use of long-term ventricular assist device therapy in patients who are less ill than patients currently eligible for destination therapy, which resulted in the R andomized E valuation of V AD I nter VE ntion before I notropic T herapy (REVIVE-IT) pilot study. The specific objective of REVIVE-IT was to compare LVAD therapy with optimal medical management in patients with less advanced HF than current LVAD indications to determine if wider application of permanent LVAD use to less ill patients would be associated with improved survival, quality of life, or functional capacity. REVIVE-IT represented an extraordinary effort to provide data from a randomized clinical trial to inform clinicians, scientists, industry, and regulatory agencies about the efficacy and safety of LVAD therapy in a population with less advanced HF. Despite significant support from the medical community, industry, and governmental agencies, REVIVE-IT failed to accomplish its goal. The reasons for its failure are instructive, and the lessons learned from the REVIVE-IT experience are likely to be relevant to any future study of LVAD therapy in a population with less advanced HF. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Preoperative atrial fibrillation may not increase thromboembolic events in left ventricular assist device recipients on midterm follow-up.
- Author
-
Xia, Yu, Stern, David, Friedmann, Patricia, and Goldstein, Daniel
- Subjects
- *
ATRIAL fibrillation , *LEFT heart ventricle , *THROMBOSIS risk factors , *THROMBOSIS complications , *TRANSIENT ischemic attack , *KAPLAN-Meier estimator - Abstract
Background Atrial fibrillation (AF) is a well-established risk factor for thromboembolic (TE) complications. AF is frequently found in patients with advanced heart failure, including patients undergoing left ventricular assist device (LVAD) implantation. However, reports on whether preoperative AF increases the risk of TE events after LVAD implantation are scarce and limited to single-center or 2-center studies. We sought to evaluate the association of preoperative AF with TE events and patient survival using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Methods A retrospective analysis of INTERMACS data of primary continuous-flow LVADs implanted between May 2012 and December 2013 was performed. Adult patients were dichotomized as having AF or no AF (NAF). TE events were defined as cerebrovascular accident, transient ischemic attack, hemolysis, arterial non–central nervous system embolism, or explant because of pump thrombosis. Kaplan-Meier analysis and multivariate Cox regression were performed for freedom from TE and patient survival. Results Of 3,909 patients identified during the study period, 838 (21.4%) had preoperative AF. Patients with AF were older, were likely to be male, and had more comorbidities ( p < 0.01). In the AF group, 236 TE events occurred in 175 (20.9%) patients. In the NAF group, 900 TE events occurred in 691 (22.5%) patients. The TE event rate was not significantly different between the 2 groups (0.36 events/patient-year in AF group vs 0.37 events/patient-year in NAF group, p = 0.60). On univariate analysis, AF was not significantly associated with freedom from TE but was associated with decreased patient survival (log-rank test p = 0.03). On multivariate analysis, AF was not significantly associated with either TE (adjusted hazard ratio 0.95; 95% confidence interval, 0.80–1.13) or patient survival (adjusted hazard ratio 1.09; 95% confidence interval, 0.91–1.31). Conclusions Analysis of INTERMACS suggests that preoperative AF may not increase the risk of postoperative TE complications or patient mortality on midterm follow-up. Longer follow-up to confirm these findings is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device.
- Author
-
Kirklin, James K., Naftel, David C., Kormos, Robert L., Pagani, Francis D., Myers, Susan L., Stevenson, Lynne W., Acker, Michael A., Goldstein, Daniel L., Silvestry, Scott C., Milano, Carmelo A., Timothy Baldwin, J., Pinney, Sean, Eduardo Rame, J., and Miller, Marissa A.
- Subjects
- *
HEART assist devices , *LEFT heart ventricle , *THROMBOSIS , *DISEASE incidence , *BODY mass index , *MEDICAL databases - Abstract
Background: Pump thrombosis remains an uncommon but potentially catastrophic complication of durable continuous-flow left ventricular assist devices (LVAD). A perceived increase in the incidence of pump thrombosis in the HeartMate II (HMII) LVAD (Thoratec, Pleasanton, CA) by clinicians prompted this analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. Methods: Between 2006 and June 2013, 8,988 United States patients aged older than 18 years received a durable LVAD. Of these, 6,910 adult patients from 132 institutions who received a HMII LVAD were entered in the INTERMACS database and constitute the study group for this analysis. Results: Overall survival (with censoring at transplant or explant for recovery) with the HMII LVAD was 80% at 1 year and 69% at 2 years and was not significantly different when stratified by era of implant. Freedom from device exchange or death due to thrombosis decreased from 99% at 6 months in 2009 to 94% in 2012 (p < 0.0001). Multivariable hazard function analysis showed risk factors for pump thrombosis included later implant year (p < 0.0001), younger age (p < 0.0001), higher creatinine (p = 0.002), larger body mass index (p = 0.004), white race (p = 0.0004), left ventricular ejection fraction above 20% (p = 0.02), and higher lactate dehydrogenase level at 1 month (p < 0.0001). Survival (p < 0.0001) and freedom from infection (p = 0.008) and cerebrovascular accident (p < 0.0001) were lower after pump exchange than after primary implant. Conclusions: Pump exchange or death due to pump thrombosis increased during 2011 and 2012, but the magnitude of the increase remained relatively small. Survival remains high (80% at 1 year) with the HMII LVAD. Risk factor analysis suggests that a number of patient-related factors contribute to the risk of thrombosis. Markedly elevated lactate dehydrogenase in the first month is a predictor of pump thrombosis. This analysis could not examine the potential role of technical factors during implant, such as sub-optimal pump or graft positioning, changes in patient management paradigms with pump speed settings, improved recognition and change in the threshold for pump exchange, or design or production changes with the pump, as contributors to the risk of pump thrombosis. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
12. Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: A single-arm prospective study
- Author
-
Patel, Snehal R., Saeed, Omar, Murthy, Sandhya, Bhatia, Vivek, Shin, Jooyoung J., Wang, Dan, Negassa, Abdissa, Pullman, James, Goldstein, Daniel J., and Maybaum, Simon
- Subjects
- *
NEUROHORMONES , *BLOOD flow , *LEFT heart ventricle , *HEART assist devices , *MYOCARDIUM , *LONGITUDINAL method , *HEART failure treatment , *THERAPEUTICS - Abstract
Background: Combining mechanical unloading by a continuous-flow left ventricular assist device (CF-LVAD) and neurohormonal blockade with heart failure medications (HFMED) is an underexplored clinical strategy to promote recovery of cardiac function in patients with advanced heart failure (HF). Methods: We implemented a clinical protocol to achieve maximal neurohormonal blockade after placement of a CF-LVAD and assessed its utility in an LVAD weaning (6,200 rpm) study. Thirty-four subjects were enrolled after CF-LVAD and were managed with aggressive, bi-weekly up-titration of HFMED. Results: Twenty-one subjects (8 with coronary artery disease, 13 with idiopathic dilated cardiomyopathy) were included in this LVAD weaning investigation. Overall, combined CF-LVAD and HFMED resulted in significant reverse remodeling with a decrease in left atrial volume index (44.7±16.0 to 31.6±12.1 ml/m2, p < 0.001) and LV internal diastolic diameter (6.7±1.5 to 6.0±1.6 cm, p = 0.003) and an increase in LV ejection fraction (17.4±6.5 to 33.1±16.2%, p < 0.001) during LVAD weaning (6,200 rpm). Five of 21 (24%) subjects demonstrated recovery of biventricular function. Exploratory analysis showed that recovered subjects had shorter duration HF, less myocardial fibrosis and less myocyte hypertrophy, and were supported at higher LVAD speeds. Conclusions: CF-LVAD support in combination with HFMED leads to significant reverse remodeling in patients with advanced HF. Using this approach, one quarter of patients demonstrated complete recovery of cardiac function. Our results suggest that bridge to recovery in the current device era is a clinically meaningful phenomenon and merits further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.